Champions Oncology (CSBR) Receivables - Other (2011 - 2026)

Champions Oncology has reported Receivables - Other for 16 years, with the latest figure at $7.5 million in Q2 2026.

• On a quarterly basis, Receivables - Other rose 39.46% year-over-year to $7.5 million in Q2 2026; TTM through Apr 2026 was $7.5 million, a 39.46% increase from a year earlier, with the FY2026 full-year figure at $7.5 million, up 39.46% from the prior year.
• Receivables - Other was $7.5 million for Q2 2026 at Champions Oncology, up from $6.2 million in the prior quarter.
• The five-year high for Receivables - Other was $7.5 million in Q2 2026, with the low at $3.7 million in Q1 2023.
• Average Receivables - Other over 5 years is $5.2 million, with a median of $5.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other retreated 10.7% in 2023, then surged 65.77% in 2024.
• Over 5 years, Receivables - Other stood at $4.3 million in 2022, then retreated by 7.28% to $4.0 million in 2023, then soared by 65.77% to $6.6 million in 2024, then increased by 8.09% to $7.2 million in 2025, then gained by 4.98% to $7.5 million in 2026.
• The last three Receivables - Other figures came in at $7.5 million (Q2 2026), $6.2 million (Q1 2026), and $7.2 million (Q4 2025), per Business Quant data.